KRAS and non-small cell lung carcinoma: To demonstrate DBP’s applicability as a biomarker for ALK-TKIs response, we employed a panel of eight NSCLC cell lines that carried the most common oncogenic drivers in NSCLC patients (KRAS, EGFR, ALK, and MET), and two other cell lines without detected alterations in these oncogenes [2, 5].